Wells Fargo
JSPR icon

Wells Fargo’s Jasper Therapeutics JSPR Stock Holding History

Wells Fargo’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$438 Sell
500
-800
-62% -$1.11K ﹤0.01% 6408
2025
Q4 		$2.38K Sell
1,300
-1,000
-43% -$2.01K ﹤0.01% 6206
2025
Q3 		$5.47K Sell
2,300
-179
-7% -$543 ﹤0.01% 6061
2025
Q2 		$13.8K Sell
2,479
-3,631
-59% -$17.9K ﹤0.01% 5870
2025
Q1 		$26.3K Sell
6,110
-1,305
-18% -$8.68K ﹤0.01% 5614
2024
Q4 		$159K Buy
7,415
+3,828
+107% +$79.7K ﹤0.01% 4928
2024
Q3 		$67.5K Sell
3,587
-138
-4% -$2.75K ﹤0.01% 5228
2024
Q2 		$84.6K Buy
3,725
+3,633
+3,949% +$87.1K ﹤0.01% 5037
2024
Q1 		$2.7K Buy
92
+31
+51% +$551 ﹤0.01% 5981
2023
Q4 		$481 Sell
61
-14
-19% -$94 ﹤0.01% 6394
2023
Q3 		$524 Sell
75
-5
-6% -$61 ﹤0.01% 6353
2023
Q2 		$1.09K Buy
80
+4
+5% +$59 ﹤0.01% 6304
2023
Q1 		$1.38K Buy
76
+49
+181% +$906 ﹤0.01% 6297
2022
Q4 		$130 Hold
27
– – ﹤0.01% 6735
2022
Q3 		$0 Buy
27
+1
+4% +$18 ﹤0.01% 7015
2022
Q2 		$0 Buy
26
+1
+4% +$28 ﹤0.01% 7158
2022
Q1 		$1K Hold
25
– – ﹤0.01% 6813
2021
Q4 		$2K Buy
+25
New +$2.34K ﹤0.01% 6887

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Wells Fargo's JSPR Position: Q1 2026 in Review

Wells Fargo reduced its Jasper Therapeutics (JSPR) stake by 62% in Q1 2026, selling an estimated $1.11K and leaving 500 shares worth $438. The position accounts for ﹤0.01% of the portfolio, ranked #6408.

Wells Fargo first reported a position in JSPR in Q4 2021 and has held it in 18 quarters since. The position peaked at $159K in Q4 2024. 58 funds tracked by Wall St. Rank hold JSPR as of Q1 2026.

  • Wells Fargo held 500 shares of Jasper Therapeutics worth $438 as of Q1 2026.
  • Wells Fargo sold 800 Jasper Therapeutics shares in Q1 2026, an estimated $1.11K.
  • Jasper Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #6408 holding.
  • Wells Fargo first reported a position in Jasper Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • Wells Fargo's Jasper Therapeutics position peaked at $159K in Q4 2024.
  • 58 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.